Key results at the highest dose (24 mg): 22.5% placebo-adjusted mean weight loss at 48 weeks 96% achieved at least 5% weight loss 87% achieved at least 10% weight loss 48% achieved at least 20% weight loss 26% achieved at least 30% weight loss 54% reduced BMI below the obesity threshold (30 kg/m2) versus 13% placebo No weight loss plateau at 48 weeks Discontinuation due to adverse events: 5.9% (CT-388) vs 1.3% (placebo) Preclinical Data# CT-388 improved glycemic control in mice and monkeys, reduced body weight, suppressed appetite, and improved metabolic dysfunction-associated steatohepatitis (MASH) pathology in mice
4, 2023), [32] See, e.g
Tested firsthand by me OVERALL SCORE Good Based on our comprehensive hands-on evaluation How we conducted this review Signed up with Mochi Health and purchased GLP-1s firsthand
(2023) Percentage of Canadian adults that are overweight or obese based on BMI from 2015 to 2022
Commenting on the guidance, Toni Brunning, vice president of the Royal College of Anaesthetists, said: We encourage patients to let their healthcare team know as early as possible in their peri-operative journey if theyre taking a GLP-1 or dual GIP/GLP-1 RA, as these medications wont necessarily show on hospital or GP records if theyve been purchased privately
Originally, given that weight loss is being increasingly acknowledged as a vital part of the treatment for T2DM, 29 one of the included trials in the efficacy meta-analysis tested retatrutide in patients with T2DM
